219 related articles for article (PubMed ID: 12570848)
1. Epothilone B and its analogs - a new family of anticancer agents.
Altmann KH
Mini Rev Med Chem; 2003 Mar; 3(2):149-58. PubMed ID: 12570848
[TBL] [Abstract][Full Text] [Related]
2. The biology and medicinal chemistry of epothilones.
Wartmann M; Altmann KH
Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):123-48. PubMed ID: 12678754
[TBL] [Abstract][Full Text] [Related]
3. Recent developments in the chemical biology of epothilones.
Altmann KH
Curr Pharm Des; 2005; 11(13):1595-613. PubMed ID: 15892665
[TBL] [Abstract][Full Text] [Related]
4. Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships.
Altmann KH; Memmert K
Prog Drug Res; 2008; 66():273, 275-334. PubMed ID: 18416309
[TBL] [Abstract][Full Text] [Related]
5. Synthesis & antitumor activity of epothilones B and D and their analogs.
Cheng H; Huang G
Future Med Chem; 2018 Jun; 10(12):1483-1496. PubMed ID: 29788770
[TBL] [Abstract][Full Text] [Related]
6. Diversity through semisynthesis: the chemistry and biological activity of semisynthetic epothilone derivatives.
Altmann KH; Gaugaz FZ; Schiess R
Mol Divers; 2011 May; 15(2):383-99. PubMed ID: 21197573
[TBL] [Abstract][Full Text] [Related]
7. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, anticancer activity and cytotoxicity of galactosylated epothilone B.
Gao H; Huang G
Bioorg Med Chem; 2018 Nov; 26(20):5578-5581. PubMed ID: 30318441
[TBL] [Abstract][Full Text] [Related]
9. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884
[TBL] [Abstract][Full Text] [Related]
10. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization.
Feyen F; Cachoux F; Gertsch J; Wartmann M; Altmann KH
Acc Chem Res; 2008 Jan; 41(1):21-31. PubMed ID: 18159935
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antitumor activity of epothilone B.
Cheng H; Huang H; Huang G
Eur J Med Chem; 2018 Sep; 157():925-934. PubMed ID: 30149324
[TBL] [Abstract][Full Text] [Related]
12. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
Fumoleau P; Coudert B; Isambert N; Ferrant E
Ann Oncol; 2007 Jul; 18 Suppl 5():v9-15. PubMed ID: 17656562
[TBL] [Abstract][Full Text] [Related]
13. 3D QSAR models of interactions between beta-tubulin and microtubule stabilizing antimitotic agents (MSAA): a survey on taxanes and epothilones.
Manetti F; Maccari L; Corelli F; Botta M
Curr Top Med Chem; 2004; 4(2):203-17. PubMed ID: 14754454
[TBL] [Abstract][Full Text] [Related]
14. Chemical synthesis and biological properties of pyridine epothilones.
Nicolaou KC; Scarpelli R; Bollbuck B; Werschkun B; Pereira MM; Wartmann M; Altmann KH; Zaharevitz D; Gussio R; Giannakakou P
Chem Biol; 2000 Aug; 7(8):593-9. PubMed ID: 11048950
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts.
Newman RA; Yang J; Raymond M; Finlay V; Cabral F; Vourloumis D; Stephens LC; Troncoso P; Wu X; Logothetis CJ; Nicolaou KC; Navone NM
Cancer Chemother Pharmacol; 2001 Oct; 48(4):319-26. PubMed ID: 11710633
[TBL] [Abstract][Full Text] [Related]
16. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).
Kowalski RJ; Giannakakou P; Hamel E
J Biol Chem; 1997 Jan; 272(4):2534-41. PubMed ID: 8999970
[TBL] [Abstract][Full Text] [Related]
17. Preclinical investigations with epothilones in breast cancer models.
Burris HA
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
[TBL] [Abstract][Full Text] [Related]
18. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for drug resistance conferred by β-tubulin mutations: a molecular modeling study on native and mutated tubulin complexes with epothilone B.
Navarrete KR; Alderete JB; Jiménez VA
J Biomol Struct Dyn; 2015; 33(12):2530-40. PubMed ID: 26081685
[TBL] [Abstract][Full Text] [Related]
20. A simplified synthesis of novel dictyostatin analogues with in vitro activity against epothilone B-resistant cells and antiangiogenic activity in zebrafish embryos.
Vollmer LL; Jiménez M; Camarco DP; Zhu W; Daghestani HN; Balachandran R; Reese CE; Lazo JS; Hukriede NA; Curran DP; Day BW; Vogt A
Mol Cancer Ther; 2011 Jun; 10(6):994-1006. PubMed ID: 21490306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
